文献速递前列腺癌

MRI引导活检策略改变前列腺癌诊断范式的分析

Analysis of Magnetic Resonance Imaging-directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis.
PubMed 文献 · Eur Urol Oncol · 2019-11-07

本文基于Cochrane诊断准确性系统评价数据,重新分析初次诊断可疑前列腺癌男性的五种MRI引导活检策略。结果显示各策略均优于传统系统活检,其中检测导向策略显著癌检出率最高,分诊导向策略可完全避免系统活检并降低过度诊断,MRI导向策略为EAU指南推荐方案。

要点

  • 检测导向策略显著癌检出率最高但未减少活检针数或过度诊断
  • 分诊导向策略完全省略系统活检,过度诊断降至14%但显著癌检出降至23%
  • MRI导向策略在MRI阳性者中最大化检出,阴性者可能漏诊

核心结论

  • 所有MRI引导活检策略相较传统系统活检均具获益,可能降低风险与伤害。
  • 以MRI导向活检管理为默认策略可优化初次诊断男性的诊断产出,相当比例人群可能仅需该检测。
  • 是否追加系统活检取决于按临床优先级权衡风险与获益。

研究设计与样本

  • 本研究为对Cochrane前列腺MRI及MRI靶向活检诊断准确性系统评价数据的配对一致性再分析。
  • 数据重构为五种独特活检策略,聚焦诊断产出与活检避免。
  • 研究对象为初次诊断可疑前列腺癌的活检初治男性。

主要发现

  • 检测导向策略显著癌检出率为28%(95%CI 24-34%),未减少活检或针数,非显著癌过度诊断为21%(18-25%)。
  • 分诊导向策略省略系统活检(减少100%),ISUP 1级过度诊断降至14%(11-17%),但显著癌检出降至23%(19-28%)。
  • MRI导向策略在MRI阳性男性中最大化显著癌检出,代价为MRI阴性男性显著癌漏诊,同时减少活检及ISUP 1级过度诊断。

关键数值与推荐

  • 显著前列腺癌定义为ISUP分级分组≥2。
  • 检测导向策略显著癌检出28%(95%CI 24-34%),过度诊断21%(18-25%)。
  • 分诊导向策略系统活检减少100%,显著癌检出23%(19-28%),ISUP 1级过度诊断14%(11-17%)。

临床怎么用

  • MRI引导活检可作为初次诊断男性的默认策略以优化诊断产出。
  • 根据MRI结果与患者风险特征,在部分男性中追加系统活检。
  • 依临床照护优先级权衡各策略的风险与获益选择路径。

局限性

  • 本文为基于Cochrane系统评价数据的再分析,非前瞻性原始研究。
  • 各策略产出差异需结合临床优先级进一步细化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of a magnetic resonance imaging (MRI)-directed diagnostic pathway in men at first prostate cancer work-up has been introduced within European prostate cancer guidelines. Differences in MRI-directed pathway yields need elaboration. OBJECTIVE: To investigate the diagnostic yields of MRI-directed diagnostic pathways in biopsy-naïve men suspected of having prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This analysis uses the data of the Cochrane diagnostic test accuracy systematic review on the utility of prostate MRI and MRI-targeted biopsy for significant disease in men at first diagnosis. The paired agreement analysis data were reformulated for five unique biopsy strategies focusing on diagnostic yields and biopsy avoidance. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Significant prostate cancer was defined as International Society of Urological Pathology (ISUP) grade group ≥2. RESULTS AND LIMITATIONS: The detection-focused pathway maximises the detection of significant disease (28% [95% confidence interval {CI} 24-34%]), while not reducing biopsy or core numbers, or the overdiagnoses of insignificant cancers (21% [18-25%]). The triage-focused pathway omits systematic biopsy use (reduction of 100%) and thereby reduces overdiagnoses of ISUP grade group 1 cancers (to 14% [11-17%]), but compromises the detection of significant disease (23% [19-28%]). The MRI-focused pathway maximises the detection of significant disease in MRI-positive men at a cost of nondetection of significant disease in MRI-negative men, thus reducing biopsies and overdiagnoses of ISUP grade 1 (strategy proposed by European Association of Urology guidelines). CONCLUSIONS: All MRI-directed biopsy pathways have beneficial outcomes compared with conventional systematic biopsy, with potentially reduced risks and harms. MRI-directed biopsy management as the default strategy optimises diagnostic yields in men at first diagnosis and may be the only test required in a significant proportion. Deploying additional systematic biopsy depends on balancing risks and benefits according to clinical care priorities. PATIENT SUMMARY: High-quality data on magnetic resonance imaging (MRI)-based prostate cancer diagnosis suggests that MRI-directed pathways are better than standard systematic biopsies in making correct diagnoses of important prostate cancers in men presenting for the first time with suspected cancer. MRI-directed diagnostics should be backed up by a systematic biopsy in selected men, according to MRI findings and patient risk profiles.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Schoots IG, Padhani AR, Rouvière O, et al. Analysis of Magnetic Resonance Imaging-directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis. Eur Urol Oncol. 2019. PMID: 31706946. doi:10.1016/j.euo.2019.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。